Engineered immune cells take on lupus and scleroderma

NCT ID NCT06434363

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment for autoimmune disorders like lupus and scleroderma. It combines specially engineered natural killer cells (AD-PluReceptor) with a drug called tafasitamab and chemotherapy to try to control the disease. The study will enroll 47 people and first check safety, then find the best dose, and finally see if it helps manage symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AD-PluReceptor-NK cells (engineered natural killer cells) plus tafasitamab and chemotherapy
What this could lead to: If successful, this could lead to a new treatment option that helps control autoimmune diseases like lupus and scleroderma by targeting faulty immune cells.
What could go wrong: This is an early-phase trial with only 47 participants, so safety and effectiveness are not yet proven. There are risks from chemotherapy and the cell therapy, including infections and immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISORDERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disease Bronchiolitis Obliterans Syndrome graft versus host disease lupus erythematosus lupus nephritis systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE DISORDERS LUPUS LUPUS NEPHRITIS SYSTEMIC LUPUS ERYTHEMATOSUS SYSTEMIC SCLEROSIS

Contacts and locations

Locations

MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
The University of Texas Health Science Center at Houston
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.